Man Group plc Acquires Shares of 195,160 Thermo Fisher Scientific Inc. $TMO

Man Group plc bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 195,160 shares of the medical research company’s stock, valued at approximately $97,845,000. Man Group plc owned about 0.05% of Thermo Fisher Scientific at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID grew its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the period. Kilter Group LLC purchased a new position in Thermo Fisher Scientific in the second quarter valued at approximately $25,000. Allied Private Wealth LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at $26,000. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the last quarter. Finally, Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $28,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1%

Shares of NYSE TMO opened at $627.96 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market cap of $232.19 billion, a P/E ratio of 33.78, a P/E/G ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00. The business has a 50-day simple moving average of $548.75 and a two-hundred day simple moving average of $510.05.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the business posted $4.28 earnings per share. The company’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several research reports. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price target for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 73,493 shares of company stock worth $43,950,381. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.